Teva Pharmaceutical Industries Limited (TLV:TEVA)
Israel
· Delayed Price · Currency is ILS · Price in ILA 6,062.00
-18.00 (-0.30%)
Jun 4, 2025, 3:45 PM IDT
Teva Pharmaceutical Industries Employees
As of December 31, 2024, Teva Pharmaceutical Industries had 35,686 total employees, including 33,892 full-time and 1,794 part-time employees. The number of employees decreased by 786 or -2.16% compared to the previous year.
Employees
35,686
Change (1Y)
-786
Growth (1Y)
-2.16%
Revenue / Employee
1.67M ILS
Profits / Employee
-129.42K ILS
Market Cap
69.40B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 35,686 | -786 | -2.16% |
| Dec 31, 2023 | 36,472 | 1,347 | 3.83% |
| Dec 31, 2022 | 35,125 | -854 | -2.37% |
| Dec 31, 2021 | 35,979 | -2,393 | -6.24% |
| Dec 31, 2020 | 38,372 | -1,667 | -4.16% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Danel (Adir Yeoshua) | 4,290 |
| Kamada | 420 |
| Bait Bakfar | 227 |
| SofWave Medical | 126 |
| BrainsWay | 120 |
| Novolog (Pharm-Up 1966) | 936 |
| Ilex Medical | 178 |
| InterCure | 320 |
Teva Pharmaceutical Industries News
- 22 hours ago - Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer - GlobeNewsWire
- 1 day ago - Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement - GlobeNewsWire
- 4 days ago - New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025 - GlobeNewsWire
- 4 days ago - Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-‘749 (olanzapine) to Date - Financial Post
- 4 days ago - Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date - GlobeNewsWire
- 6 days ago - Teva Reaffirms Growth Strategy, Eyes $5 Billion Innovative Franchise By 2030 - Benzinga
- 6 days ago - Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day - GlobeNewsWire
- 7 days ago - Teva wins new Buy at Truist ahead of Innovation & Strategy Day - Seeking Alpha